October 8, 2014
1 min read
Add Us On GoogleAdd SciAmFirst Ebola Patient Dies in the U.S.
Critical care at Dallas hospital failed to prevent patient from succumbing to virus acquired in Liberia
By Dina Fine Maron
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
The first Ebola patient diagnosed in the U.S. died this morning in Dallas at 7:51 A.M. local time. The sad news was announced by the facility offering his care, Texas Health Presbyterian Hospital Dallas, in an emailed statement this morning that read:
“It is with profound sadness and heartfelt disappointment that we must inform you of the death of Thomas Eric Duncan this morning at 7:51 am. Mr. Duncan succumbed to an insidious disease, Ebola. He fought courageously in this battle. Our professionals, the doctors and nurses in the unit, as well as the entire Texas Health Presbyterian Hospital Dallas community, are also grieving his passing. We have offered the family our support and condolences at this difficult time.”
Texas health official David Lakey, commissioner of the state’s health department, also offered his condolences to the family and said, in a statement, that the past week was an “enormous test of our health system.”
The patient, who had been admitted to the hospital on September 28 after contracting the virus in Liberia, had been placed on a ventilator and was receiving dialysis in the final days before his death.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber